-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GYnAOef8y3QpOE3bMjCdgrfj7JCg8+Oyq+wVZ8NZpkMSJaU/nStoW1c4hwR/8Lm5
 ybxNlSGIPnHVL2VS697PmQ==

<SEC-DOCUMENT>0001209191-08-042138.txt : 20080710
<SEC-HEADER>0001209191-08-042138.hdr.sgml : 20080710
<ACCEPTANCE-DATETIME>20080710171530
ACCESSION NUMBER:		0001209191-08-042138
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20080522
FILED AS OF DATE:		20080710
DATE AS OF CHANGE:		20080710

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LA JOLLA PHARMACEUTICAL CO
		CENTRAL INDEX KEY:			0000920465
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330361285
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		6455 NANCY RIDGE DR
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584526600

	MAIL ADDRESS:	
		STREET 1:		6455 NANCY RIDGE DR
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			SEIKKULA LUKE
		CENTRAL INDEX KEY:			0001391435

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24274
		FILM NUMBER:		08947690

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		8586466649

	MAIL ADDRESS:	
		STREET 1:		6455 NANCY RIDGE DRIVE
		CITY:			SAN DIEGO
		STATE:			X1
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>doc4a.xml
<DESCRIPTION>FORM 4/A SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2008-05-22</periodOfReport>

    <dateOfOriginalSubmission>2008-05-23</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000920465</issuerCik>
        <issuerName>LA JOLLA PHARMACEUTICAL CO</issuerName>
        <issuerTradingSymbol>LJPC</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001391435</rptOwnerCik>
            <rptOwnerName>SEIKKULA LUKE</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>6455 NANCY RIDGE DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92121</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Vice President Manufacturing</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Options (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.82</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2008-05-22</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>75000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2018-05-22</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>75000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>75000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The options vest and become exercisable one business day if and after La Jolla Pharmaceutical Company receives written approval of its New Drug Application (&quot;NDA&quot;) for Riquent from the United States Food and Drug Administration provided that such approval is received within 18 months of the NDA filing.</footnote>
    </footnotes>

    <remarks>Amendment is correcting Transaction Date and related exercise price.</remarks>

    <ownerSignature>
        <signatureName>/s/ Gail A. Sloan
Attorney-in-fact for Luke Seikkula</signatureName>
        <signatureDate>2008-07-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----